SOLIGENIX, INC. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SOLIGENIX, INC. stock issued during period, shares, new issues for the quarter ending 2019-09-30 was 0.00 shares.
- SOLIGENIX, INC. stock issued during period, shares, new issues for the quarter ending 2011-12-31 was 0.00 shares.
- SOLIGENIX, INC. stock issued during period, shares, new issues for the quarter ending 2011-09-30 was 0.00 shares.
- SOLIGENIX, INC. stock issued during period, shares, new issues for fiscal 2011 was 0.00 shares.
- SOLIGENIX, INC. stock issued during period, shares, new issues for fiscal 2010 was 0.00 shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2015-12-31 | 3.94M shares 10-Q · filed 2016-05-12 | |
| 2011-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-27 | 0.00 shares 10-K · filed 2012-03-27 |
| 2011-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | |
| 2010-12-31 | 0.00 shares 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |